Daily FNArena News - Small Caps

PS&C had to make its first downgrade to guidance since listing on ASX amidst generalised weakness in the IT sector.

CLSA learns Cover-More is protected against some of the pitfalls for travel insurers, changing tack on the stock. Bell Potter also initiates coverage with a Buy rating.

Baillieu Holst takes a look at the significant upside for Cellmid’s cancer targeting technology.

Virtus Health has made its first acquisition since listing, a 70% stake in an Irish IVF clinic.

Stem cell developer Cynata Technologies has found a fan in Baillieu Holst because of the potential to revolutionise regenerative medicine.

Thorn Group is showing signs of growth after flatlining in recent years but brokers are reserving judgement.

Select Harvests has been troubled by rainfall as it harvests the almond crop but strong prices provide an offset.

Brokers consider Virtus Health has good growth potential, supported by changing demographics.

Brokers take a closer look at Vocus Communications and the trajectory for its dark fibre.

Rare earth producer Lynas Corp has averted a cash shortage for now with a planned equity raising and debt restructure.